Eurofins Biomnis code

GOLIM

Synonyms

• Simponi®

Specialty

Immunology

Clinical significance

Golimumab (Simponi®) is a fully human monoclonal antibody targeted against TNF alpha. It is used to treat severe forms of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and haemorrhagic rectocolitis. It is taken monthly alone or in combination with methotrexate. It is available in the form of a 50 mg auto-injecting ¿pen¿ that injects subcutaneously. It can induce the production of antibodies by the patient that will neutralise its effect. In patients in whom golimumab treatment is ineffective, it is therefore justified to test for anti-golimumab antibodies. The test combines the assay of golimumab and the assay of anti-Golimumab antibodies.

Preanalytics

• 1 mL :
• serum
•   FROZEN before sending

• A tube specifically for this analysis : No

Further information

Enclose the specific clinical information form (R49G-INTGB)
Always draw blood at the same time before another administration
Please attach the specific clinical information sheet (R46 : Anti-TNF)

Documents to download

• Specific

Methodology

Enzyme-immunoassay

Turnaround time

30 days

Caption